MedTrace Logo

Delayed CNI-based Immunosuppression With Advagraf After MELD-based Liver Transplantation

NCT01781195 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2015-05-28

No results posted yet for this study

Summary

Prolonged-release low-dose Advagraf should better protect from CNI-side effects compared to standard immunosuppressive regiments while the rate of rejection is not increased and thus graft function is well maintained. We hypothesize that especially in high-MELD (MELD-score \>20) recipients who have a decreased immune competence the prolonged-release low-dose Advagraf concept would better protect from side effects of immunosuppression (i.e. infection). Nevertheless, we assume that also patients with a MELD-score ≤20 will benefit from this concept in regard to lower infection rates and less side effects of immunosuppression.

Conditions

  • Liver Graft Dysfunction

Sponsors & Collaborators

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Peter Schemmer, Prof. · University Hospital Heidelberg

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-08-31
Completion
2015-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01781195 on ClinicalTrials.gov